Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCL

Constantine S. Tam, MD
Published: Wednesday, Oct 25, 2017



Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Toxicities that were seen with the combination were what was expected from the 2 drugs individually, states Tam. Ibrutinib had side effects in terms of bruising and bleeding. Venetoclax had reflux symptoms and neutropenia, which are both expected, explains Tam. Importantly, neither one of these toxicities was higher when the drugs were given in combination compared with monotherapy.

This treatment requires 8 tablets a day, and none of the patients had to stop their treatment because of toxicities.
 
SELECTED
LANGUAGE


Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the toxicities associated with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).

Toxicities that were seen with the combination were what was expected from the 2 drugs individually, states Tam. Ibrutinib had side effects in terms of bruising and bleeding. Venetoclax had reflux symptoms and neutropenia, which are both expected, explains Tam. Importantly, neither one of these toxicities was higher when the drugs were given in combination compared with monotherapy.

This treatment requires 8 tablets a day, and none of the patients had to stop their treatment because of toxicities.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x